GlassScriptPhysician profile
Pusadee Suchinda
NPI 1194817932
$11,761.02
in general payments reported to CMS, 2019-2025
54 companies · $383 in 2025
The $383 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,500 · 2020: $1,034 · 2021: $1,933 · 2022: $2,284 · 2023: $2,832 · 2024: $1,795 · 2025: $383.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,969 · Education: $40.50.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,969.40 |
| Education | $40.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,338.66 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $1,210.00 | 2019-2025 | Krystexxa, Tavneos, Tepezza |
| Horizon Therapeutics Plc | $1,143.47 | 2019-2023 | Krystexxa, Tepezza |
| Astrazeneca Pharmaceuticals LP | $819.65 | 2019-2024 | Farxiga, Lokelma |
| Otsuka America Pharmaceutical, INC. | $722.52 | 2019-2024 | Jynarque |
| Vifor Pharma, INC. | $552.28 | 2019-2024 | Veltassa |
| Lilly USA, LLC | $463.37 | 2020-2024 | Jardiance, Mounjaro |
| Mallinckrodt Hospital Products INC. | $445.60 | 2020-2023 | Acthar |
| Novartis Pharmaceuticals Corporation | $377.12 | 2019-2025 | |
| Aurinia Pharma U.S., INC. | $369.29 | 2022-2024 | Lupkynis |
| Bayer Healthcare Pharmaceuticals INC. | $352.93 | 2021-2024 | |
| Abbott Laboratories | $319.89 | 2020-2024 | Freestyle Libre 3 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $310.12 | 2020-2025 | Jardiance, Synjardy, Tradjenta |
| Glaxosmithkline, LLC. | $291.07 | 2020-2024 | Benlysta, Jesduvroq |
| Merck Sharp & Dohme LLC | $270.13 | 2021-2024 | Verquvo |
Show all 51 companies
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Pusadee Suchinda listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.